Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
2023-506687-13-00Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in generalized tonic-clonic seizure (GTCS) and idiopathic epilepsy (IGE) comparing Cenobamate adjunctive therapy with Placebo adjunctive therapy (2 arms). Started Jul 2024; status: completed.
02
Drugs
cenobamate
03
Conditions
generalized tonic-clonic seizure (GTCS)idiopathic epilepsy (IGE)
Beyond the preview
Go deeper on 2023-506687-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506687-13-00.